Walmart to Cut PhonePe Stake in IPO as Tiger Global and Microsoft Exit 
Memory Chip Shortage Drives Higher Gadget Prices and Weakens Global Tech Demand 
Ericsson Plans SEK 25 Billion Shareholder Returns as Margins Improve Despite Flat Network Market 
Global DRAM Chip Shortage Puts Automakers Under New Cost and Supply Pressure 
Lynas Rare Earths Shares Surge as Quarterly Revenue Jumps on Strong Prices 
Intel Stock Slides Despite Earnings Beat as Weak Q1 Outlook Raises Concerns 
Morgan Stanley Flags High Volatility Ahead for Tesla Stock on Robotaxi and AI Updates 
Baidu Shares Surge After Official Launch of Advanced Ernie 5.0 AI Model 
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors 
JPMorgan and Allen & Company Emerge as Big Winners in Warner Bros Discovery Bidding War 
Sanofi Reports Positive Late-Stage Results for Amlitelimab in Eczema Treatment 
BitGo IPO Prices Above Range, Raises $212.8M in Landmark Crypto Market Debut 
United Airlines Posts Record Q4 Revenue as Premium Demand Lifts Earnings 
FSU Criticizes ANZ Over Suncorp Bank Job Cuts Amid Post-Acquisition Commitments 
SoftBank Shares Surge as AI Optimism Lifts Asian Tech Stocks 
Tesla Plans FSD Subscription Price Hikes as Autonomous Capabilities Advance 
Trump Signs Executive Order to Limit Wall Street Investment in Single-Family Homes 
SAN DIEGO, May 04, 2017 -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that Apricus’ first quarter 2017 financial results will be released on Thursday, May 11, 2017 at 4:01 p.m. Eastern Time. Company management will host a conference call on Thursday, May 11, 2017, at 4:30 p.m. Eastern Time to discuss the financial results and other recent corporate highlights.
To participate by telephone, please dial (855) 780-7196 (Domestic) or (631) 485-4867 (International). The conference ID number is 18008306. The live audio webcast can be accessed via the Investor Relations’ section of Apricus’ website at www.apricusbio.com. Please log in approximately 5-10 minutes before the event to ensure a timely connection. The archived webcast will remain available for 30 days following the live call.
About Apricus Biosciences, Inc.
Apricus Biosciences, Inc. (APRI) is a biopharmaceutical company advancing innovative medicines in urology and rheumatology. Apricus has two product candidates currently in development. Vitaros is a product candidate in the United States for the treatment of erectile dysfunction, which is in-licensed from Warner Chilcott Company, Inc., now a subsidiary of Allergan plc (Allergan). RayVa is our product candidate in Phase 2 development for the treatment of the circulatory disorder Raynaud’s phenomenon, secondary to scleroderma, for which Apricus owns worldwide rights.
For further information on Apricus, visit http://www.apricusbio.com.
Vitaros™ is Apricus’ trademark in the United States, which is pending registration and subject to the agreement with Allergan. Vitaros® is a registered trademark of Ferring International Center S.A. in certain countries outside of the United States. RayVa™ is Apricus’ trademark, which is registered in certain countries throughout the world and pending registration in the United States.
CONTACT: Institutional / Retail Investors: Matthew Beck [email protected] The Trout Group LLC (646) 378-2933
